Tom Hodge, PhD, formerly with the CDC and now presenting on behalf of Float Pharma, a venture that’s developed a way to identify proteins in the case of COVID-19 don’t’ mutate. According to Hodges this approach “wipes out the virus” and includes therapeutic attributes. In this sense this investigational agent represents the potential for both vaccine and therapeutic but has only been conducted in preclinical research. Their investigational FLOVID-20 uses inhalational delivery of a preventative and therapeutic immuno-stimulatory biomedicine targeted nucleocapsid epitopes on SARS-COV-2. Sponsored by the COVID-19 Early Treatment Fund (CETF) watch to better understand the speaker’s point of view.